Lonza Confirms Talks with South African Government Regarding the Establishment of a Joint Venture

Lonza Confirms Talks with South African Government Regarding the Establishment of a Joint Venture
Basel, Switzerland, 10 February 2012 - Lonza confirms to be in discussions and negotiations with the South African Government regarding the establishment of a local joint venture called Ketlaphela for the establishment of a local manufacturing facility for Anti-Retroviral Medicines. The discussions are still at an early stage and nothing has been signed.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.
Further Information Lonza Group Ltd Lonza Group Ltd Lonza Group Ltd Head of Corporate Communications Investor Relations Media Relations
Dominik Werner Dirk Oehlers Melanie Disa
Tel +41 61 316 8798 Tel +41 61 316 8540 Tel +1 201 316 9413
Fax +41 61 316 9798 Fax +41 61 316 9540 Fax +1 201 696 3533
[email protected] [email protected] [email protected]

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.